When was Oncimmune founded?

Oncimmune was founded in 2006 and raised its 1st funding round 5 years after it was founded.

Where is Oncimmune located?

Oncimmune is headquartered in Cambridge, United States.

How many employees does Oncimmune have?

As of Jul 31, 2026, the latest employee count at Oncimmune is 34.

Is Oncimmune a funded company?

Oncimmune is a funded company, having raised an undisclosed amount across 17 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 01, 2011.

When was the latest funding round of Oncimmune?

Oncimmune's latest funding was a $***** Post IPO round on Oct 21, 2024, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.79B in funding in 2026 to date.

Where does Oncimmune rank among its competitors?

Oncimmune ranks 137th amongst 898 active competitors, of which 232 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Chai Discovery, which secured $400M in Jul, 2026.

Who are the top competitors of Oncimmune?

Oncimmune's top competitors include Natera, Guardant Health and Adaptive Biotechnologies. Among them, Chai Discovery secured the most recent funding round in July, 2026.

Oncimmune - 2026 Company Profile, Team, Funding, Competitors & Financials

Oncimmune is an acquired company based in Cambridge (United States), founded in 2006 by Geoffrey Hamilton-Fairley. It operates as an Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. Oncimmune has raised an undisclosed amount in funding. The company has 898 active competitors, including 232 funded and 162 that have exited. Its top competitors include companies like Natera, Guardant Health and Adaptive Biotechnologies.

Company Details

Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. It leverages its proprietary ImmunoINSIGHTS platform, which uses large-scale autoantibody profiling and immune system analysis to generate actionable insights for drug development and patient stratification. Its technology enables pharmaceutical and biotechnology partners to identify disease-specific immune signatures, supporting earlier diagnosis, improved therapy development, and more precise treatment selection.

Website: www.oncimmune.com/
Social
Email ID: *****@oncimmune.com

Key Metrics

Founded Year

2006

Location

Cambridge, United States

Stage

Acquired

Latest Funding Round

Post IPO, Oct 21, 2024, $*****

Investors

IPF Partners & 10 more

Ranked

137^th among 898 active competitors

Employee Count

34 as on Jul 31, 2026

Investment & Acquisitions

Protagen

Similar Companies

Natera & 1098 more

Exit Details

Acquired by Alden Scientific (Jul 14, 2025)

View Oncimmune's full profile

Oncimmune is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ONCIMMUNE HOLDINGS PLC CIN: 9818395 , Germany, Active	Oct 08, 2015	-	52 (As on May 31, 2021)

Oncimmune got acquired by Alden Scientific on Jul 14, 2025.

Click here to take a look at Oncimmune's acquisition in detail

Oncimmune has raised funding over 17 rounds. Its first funding round was on May 01, 2011. Oncimmune has 11 institutional investors.

Here is the list of recent funding rounds of Oncimmune:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 21, 2024	7285748	Post IPO	4411657	2284664	5834593	1778231
Dec 15, 2022	9960401	Post IPO	1040263	1711895	5837571	8984215
Mar 25, 2021	7223380	Post IPO	8207472	4093639	2132313	2217168

Access funding benchmarks and valuations. Sign up today!

View details of Oncimmune's funding rounds and investors

The founders of Oncimmune is Geoffrey Hamilton-Fairley.

Here are the details of Oncimmune's key team members:

Geoffrey Hamilton-Fairley: Former Founder of Oncimmune.

View details of Oncimmune's Founder profiles and Board Members

Oncimmune's employee count trend

Oncimmune has 34 employees as of Jul 26. Here is Oncimmune's employee count trend over the years:

Uncover Oncimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Oncimmune include Natera, Guardant Health and Adaptive Biotechnologies. Here is the list of Top 10 competitors of Oncimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	75/100
3rd	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
5th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
6th	Chai Discovery 2023, San Francisco (United States), Series C	Developer of artificial intelligence models for de novo molecular design	$630M	Kleiner Perkins, Oak HC/FT & 28 others	69/100
7th	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
10th	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
137th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, WG Partners & 9 others	42/100